This article is more than 5 years old. Information may no longer be current.

FDA responds to NDA for glaucoma drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has sent a complete response letter to Valeant Pharmaceuticals regarding the new drug application for the Bausch + Lomb latanoprostene bunod ophthalmic solution 0.024% product called Vyzulta.

The investigational single-agent IOP-lowering eye drop is intended for treatment of open angle glaucoma or ocular hypertension.

The letter “only refers to a current good manufacturing practice (CGMP) inspection at Bausch + Lomb's manufacturing facility in Tampa, Fla.,” and “did not identify any efficacy or safety concerns with respect to the NDA or additional clinical trials needed for the approval of the NDA,” according to a press release from Valeant.

A PDUFA date for the product had been slated for Aug. 24.